Iva Truxova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Type I interferon and cancer.

Type I interferon and cancer.

Journal: Immunological reviews

Published: September 05, 2023

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.

Journal: Journal for immunotherapy of cancer

Published: February 07, 2023

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.

Journal: Cell death & disease

Published: November 17, 2022

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.

Journal: Oncoimmunology

Published: March 24, 2021

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.

Journal: Journal for immunotherapy of cancer

Published: July 21, 2020

Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death.

Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death.

Journal: Methods in enzymology

Published: February 01, 2020

Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood.

Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood.

Journal: Methods in enzymology

Published: January 18, 2020

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients.

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients.

Journal: Journal for immunotherapy of cancer

Published: July 08, 2019

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.

Journal: Haematologica

Published: April 08, 2019

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 20, 2018

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Journal: Journal for immunotherapy of cancer

Published: October 26, 2018

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

Journal: Journal for immunotherapy of cancer

Published: August 16, 2018

Showing 1-12 of 23

Last Updated: 09/26/2026